What we do

Our mission is to transform cancer care through large-scale molecularly-informed clinical research.

Traditional oncology drug development and clinical care paradigms, emphasizing uniformity of management, are ill-suited to the precision oncology era of patient-centered trials and care. We believe a new model that integrates molecular profiling and cutting-edge clinical research will dramatically improve treatment options, while speeding the path to drug approvals. 

Our goal is to create a new standard of care for cancer patients, one where molecular profiling, clinical trial participation and continuous learning to inform care and research are the norm.  

 

History

Strata Oncology was founded in 2016 by leading physicians and scientists with a shared vision for realizing the promise of precision medicine for cancer patients. Since then we have raised $38 million in venture capital and partnered with leading health systems and biopharmaceutical companies to create a future in which all cancer patients have access to the best precision care.

 
  Co-founders Scott Tomlins MD, PhD and Dan Rhodes, PhD

Co-founders Scott Tomlins MD, PhD and Dan Rhodes, PhD

 

Investors

merck.jpg
Pfizer.svg.png
baird.jpg
deerfield.png
Arboretum.png
RVCF-logo.jpg
elab.png
Thermo.jpg
 

Board of Directors

 

Bill Burkoth               Executive Director, Pfizer Ventures

Keith Flaherty, MD    Co-founder, Strata Oncology, Professor, Harvard Medical School, Oncologist, MGH            

Jan Garfinkle             Founder and Managing Director, Arboretum Ventures

Dan Rhodes, PhD       President & CEO, Co-founder, Strata Oncology

Prem Tumkosit           Investment Principal, Merck Global Health Innovation Fund

Nicole Walker            Director, Venture Capital, Baird Capital

Jeff Williams             Founder & CEO, NeuMoDx Molecular